Reduction Therapy of Alanine Aminotransferase Levels Prevent HCC Development in Patients with HCV-associated Cirrhosis

Background: To find a way to prevent the development of hepatocellular carcinoma (HCC) from hepatitis C virus-associated liver cirrhosis (HCV-LC), an analysis of the HCV-LC patients who had received reduction therapy of the alanine aminotransferase (ALT) levels was performed. Patients and Methods: S...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2006-05, Vol.26 (3B), p.2221-2226
Main Authors: RINO, Yasushi, TARAO, Kazuo, TAKANASHI, Yoshinori, IMADA, Toshio, MORINAGA, Souichiro, OHKAWA, Shinichi, MIYAKAWA, Kaoru, HIROKAWA, Satoru, MASAKI, Takahiro, TARAO, Norio, YUKAWA, Norio, SAEKI, Hiroyuki
Format: Article
Language:English
Subjects:
Alanine Transaminase - blood
Biological and medical sciences
Carcinoma, Hepatocellular - enzymology
Carcinoma, Hepatocellular - prevention & control
Carcinoma, Hepatocellular - virology
Drugs, Chinese Herbal - therapeutic use
Female
Gastroenterology. Liver. Pancreas. Abdomen
Glycyrrhizic Acid - therapeutic use
Hepacivirus
Hepatitis C virus
Hepatitis C, Chronic - complications
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - enzymology
Humans
Liver Cirrhosis - complications
Liver Cirrhosis - drug therapy
Liver Cirrhosis - enzymology
Liver Cirrhosis - virology
Liver Neoplasms - enzymology
Liver Neoplasms - prevention & control
Liver Neoplasms - virology
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Male
Medical sciences
Middle Aged
Other diseases. Semiology
Protoporphyrins - therapeutic use
Retrospective Studies
Tumors
Ursodeoxycholic Acid - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: To find a way to prevent the development of hepatocellular carcinoma (HCC) from hepatitis C virus-associated liver cirrhosis (HCV-LC), an analysis of the HCV-LC patients who had received reduction therapy of the alanine aminotransferase (ALT) levels was performed. Patients and Methods: Seventy-four consecutive HCV-LC patients of Child Stage A were followed for >10 years for the development of HCC. They were divided into two groups: in group A, the reduction therapy for the ALT levels was aggressively performed, while in group B, the reduction therapy was not performed aggressively. The patients were subdivided into three sub-groups according to their serum ALT levels. In groups A and B, the high ALT group was comprised, respectively, of nine and five patients whose annual average serum ALT levels were persistently high (≥80 IU), while the low ALT group was comprised of 19 and 20 patients whose annual average serum ALT levels were persistently low (
ISSN:0250-7005
1791-7530